WO2026028091 - METHODS AND COMPOSITIONS FOR TREATING OBESITY AND OTHER DISORDERS
National phase entry is expected:
Publication Number
WO/2026/028091
Publication Date
05.02.2026
International Application No.
PCT/IB2025/057653
International Filing Date
29.07.2025
Title **
[English]
METHODS AND COMPOSITIONS FOR TREATING OBESITY AND OTHER DISORDERS
[French]
MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE L'OBÉSITÉ ET D'AUTRES TROUBLES
Applicants **
CANARY CURE THERAPEUTICS, INC.
Inventors
REDDY, R. Raj
Priority Data
63/676,596
29.07.2024
US
63/692,899
10.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6960 | |
| EPO | Filing, Examination, Granting | 92885 | |
| Japan | Filing, Examination, Granting | 4560 | |
| South Korea | Filing, Examination, Granting | 7330 | |
| USA | Filing, Examination, Granting | 25790 |
Total:
137,525
Contact Us
Abstract[English]
Provided herein are CB1R targeting inhibitory RNA oligonucleotides and compositions thereof. Also provided herein are methods for treating CB1R associated disorders with the CB1R targeting inhibitory RNA oligonucleotides and compositions described herein. Also provided herein are inhibitory RNA oligonucleotides specific for ZNF423 mRNA, or TLE3 mRNA, and methods of use thereof.[French]
L'invention concerne des oligonucléotides d'ARN inhibiteurs de ciblage de CB1R et des compositions de ceux-ci. L'invention concerne également des méthodes de traitement de troubles associés à CB1R avec les oligonucléotides d'ARN inhibiteurs de ciblage de CB1R et des compositions décrites dans la description. L'invention concerne également des oligonucléotides d'ARN inhibiteurs spécifiques de l'ARNm de ZNF423, ou de l'ARNm de TLE3, et leurs procédés d'utilisation.